Superworth

Sanara MedTech revenue SMTI

Sales by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
$109.8M
Latest quarter, Q2 FY26
$28.1M
+9% on a year earlier
Fiscal year 2025
$103.1M
+19% on the year before

Sanara MedTech's revenue was $109.8M over the twelve months to Jun 30, 2026, up 13% on a year earlier.

In its latest quarter, Q2 FY26, it was $28.1M, up 9% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 46% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$103.1M+19%
FY2024$86.7M+33%
FY2023$65M+42%
FY2022$45.8M+90%
FY2021$24.1M+55%
FY2020$15.6M+32%
FY2019$11.8M+102%
FY2018$5.8M−7%
FY2017$6.3M+14%
FY2016$5.5M+63%
FY2015$3.4M+28%
FY2014$2.6M+52%
FY2013$1.7M+47%
FY2012$1.2M−47%
FY2011$2.2Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$28.1M+9%$109.8M
Q1 FY26$27.8M+19%$107.5M
Q4 FY25$27.5M+5%$103.1M
Q3 FY25$26.3M+22%$101.9M
Q2 FY25$25.8M+28%$97.2M
Q1 FY25$23.4M+26%$91.6M
Q4 FY24$26.3M+49%$86.7M
Q3 FY24$21.7M+35%$78.1M
Q2 FY24$20.2M+28%$72.4M
Q1 FY24$18.5M+19%$68M
Q4 FY23$17.7M+15%$65M
Q3 FY23$16M+23%$62.6M

Against its peers

Companies in Medical - Instruments & Supplies nearest Sanara MedTech's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
SMTISanara MedTech$109.8M+13% a year
INFUInfuSystem$143.3M+2% a year
EMBCEmbecta$1B−8% a year
UTMDUtah Medical Products$36.1M−7% a year
PDEXPro DEX$77.5M+16% a year
TCMDTactile Systems Technology$350.3M+17% a year
MDXGMimedx$355.2M−2% a year
MOVMovado$689.9M+5% a year
KEQUKewaunee Scientific$277.2M+5% a year
IRMDIradimed$86.3M+11% a year
STAAStaar Surgical$339.6M+51% a year
Peer median$308.4M

Where Sanara MedTech ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Sanara MedTech

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.